Eczema Clinical Research Studies

Interested in joining a clinical research trial?

Atopic dermatitis, or eczema, is the most common chronic inflammatory, pruritic skin disease. It causes intense itching and scratching which leads to a severe rash. Recent eczema studies have given researchers more information about this disease, which is leading to a better understanding of the ailment and new treatment options. There are currently a variety of eczema studies available at our center for patients with mild to severe atopic dermatitis. These studies include treatments such as biologics (complicated molecules that are manufactured within a living organism), a topical gel, and an oral medication designed to help decrease extremely itchy skin involved with eczema. These study medications are at the forefront of current medicine and are provided at absolutely no cost, and with no insurance needed. You may also be reimbursed for your time and travel and will receive care from a physician affiliated with the Clinical Research Center of Alabama.

For more information on any of the following eczema clinical research studies, please contact Will O’Donnell by calling 205.209.4179 or emailing wodonnell@alabamaallergy.com

Biologic Injection Study

Age 12-17

Leo1334

This study is to evaluate the efficacy and safety of Tralokinumab monotherapy in subjects with moderate to severe atopic dermatitis who are candidates for systemic therapy. There are a total of 29 visits over a span of 72 weeks.

Biologic Injection Study

Ages 6 months-6 years

Rengeneron 1539

A phase 2/3 study investigating the pharmacokinetics, safety, and efficacy of Dupilumab in patients aged ≥6 months to < 6years with severe atopic dermatitis.

Oral Medication

Age 12+

Pfizer1012

A Phase 3, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of PF-0496582 monotherapy in subjects aged 12 years and older, with moderate to severe atopic dermatitis.

Biologic Injection Study

Ages 6 years – 12 years

Regeneron1652

A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab administered concomitantly with topical corticosteroids in patients ≥6 years to <12 years of age, with severe atopic dermatitis.

Biologic Injection Study

Age 19+

Glenmark

This research study is being done to evaluate if the investigational drug, GBR 830, is safe and effective in subjects with moderate to severe atopic dermatitis. This study is also looking at the biological activity of GBR 830 and how it is eliminated from the body.

Oral Medication

Age 19-70

Vanda

The purpose of this study is to evaluate the effect of an investigational drug called Tradipitant on symptoms associated with atopic dermatitis with atopic dermatitis and to assess the safety of Tradipitant.

Oral Medication

Age 12+

Pfizer1014

The purpose of this study is to evaluate the effect of the study drug on moderate to severe atopic dermatitis

Oral Medication - Add-On Therapy

Age 12-75

AbbVie

The purpose of this study is to compare the effectiveness and safety of upadacitinib (ABT-494) to placebo (pill without any active substance that looks like upadacitinib) in combination with topical corticosteroids for adolescents (12-17 years of age) and adults (18-75 years of age with moderate to severe atopic dermatitis (AD).

Topical Cream

Age 19+

Leo1275

The purpose of this study is to evaluate the safety and effectiveness of Delgocitinib cream on adult patients with moderate to severe atopic dermatitis.

Become a Participant in our Eczema Studies

If you’re interested in participating in a clinical research study at the Clinical Research Center of Alabama, call 205.209.4100 to speak with an experienced coordinator or fill out the contact form below.